SQZ Biotechnologies Company
SQZB
$0.028
$0.000.00%
| Weiss Ratings | SQZB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | SQZB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | SQZB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.07 | |||
| Price History | SQZB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | -60.00% | |||
| 60-Day Total Return | -6.67% | |||
| 90-Day Total Return | 1.82% | |||
| Year to Date Total Return | -6.67% | |||
| 1-Year Total Return | -40.04% | |||
| 2-Year Total Return | -95.13% | |||
| 3-Year Total Return | -99.39% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -75.86% | |||
| 52-Week Low % Change | 33.33% | |||
| Price | SQZB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.12 | |||
| 52-Week Low Price | $0.02 | |||
| 52-Week Low Price (Date) | May 06, 2024 | |||
| 52-Week High Price (Date) | May 29, 2024 | |||
| Valuation | SQZB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 825.75K | |||
| Enterprise Value | 12.10M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.43 | |||
| Earnings Per Share Growth | -10.86% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.07 | |||
| Price/Book (Q) | 0.44 | |||
| Enterprise Value/Revenue (TTM) | 1.00 | |||
| Price | $0.03 | |||
| Enterprise Value/EBITDA (TTM) | -0.21 | |||
| Enterprise Value/EBIT | -0.20 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | SQZB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 29.49M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | SQZB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 617 758 8672 | |||
| Address | 200 Arsenal Yards Boulevard Watertown, MA 02472 | |||
| Website | www.sqzbiotech.com | |||
| Country | United States | |||
| Year Founded | 2013 | |||
| Profitability | SQZB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -500.37% | |||
| Profit Margin | -591.06% | |||
| Management Effectiveness | SQZB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -41.06% | |||
| Return on Equity | -- | |||
| Income Statement | SQZB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 12.12M | |||
| Total Revenue (TTM) | 12.12M | |||
| Revenue Per Share | $0.41 | |||
| Gross Profit (TTM) | -39.67M | |||
| EBITDA (TTM) | -58.95M | |||
| EBIT (TTM) | -60.65M | |||
| Net Income (TTM) | -71.64M | |||
| Net Income Avl. to Common (TTM) | -71.64M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -4.40% | |||
| EPS Diluted (TTM) | -2.43 | |||
| EPS Diluted Growth (Q YOY) | -3.67% | |||
| Balance Sheet | SQZB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 10.19M | |||
| Cash Per Share (Q) | $0.35 | |||
| Total Current Assets (Q) | 12.09M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 1.88M | |||
| Current Ratio (Q) | 1.369 | |||
| Book Value Per Share (Q) | $0.06 | |||
| Total Assets (Q) | 29.79M | |||
| Total Current Liabilities (Q) | 8.83M | |||
| Total Debt (Q) | 21.47M | |||
| Total Liabilities (Q) | 27.91M | |||
| Total Common Equity (Q) | 1.88M | |||
| Cash Flow | SQZB - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -43.00K | |||
| Cash from Financing (TTM) | 331.00K | |||
| Net Change in Cash (TTM) | -74.05M | |||
| Levered Free Cash Flow (TTM) | -29.44M | |||
| Cash from Operations (TTM) | -74.33M | |||
